Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Jandeleit-Dahm

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Drug Targets. Cardiovascular & Haematological Disorders|March 1, 2006
Preventing atherosclerosis with angiotensin-converting enzyme inhibitors: emphasis on diabetic atherosclerosisT J Allen, K A Jandeleit-Dahm
PPAR Research|March 27, 2012
The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetesM C Thomas, K A Jandeleit-Dahm, C Tikellis
Diabetologia|February 8, 2006
Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammationA C Calkin, M E Cooper, K A Jandeleit-Dahm, et al.
Diabetes & Metabolism|September 2, 2015
Linking RAGE and Nox in diabetic micro- and macrovascular complicationsC Koulis, A M D Watson, S P Gray, et al.
Current Pharmaceutical Design|September 28, 2007
PPARs and diabetes-associated atherosclerosisA C Calkin, K A Jandeleit-Dahm, E Sebekova, et al.
Diabetologia|July 3, 2008
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammationA C Calkin, S Giunti, K J Sheehy, et al.
Diabetologia|March 1, 2012
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetesK Huynh, H Kiriazis, X-J Du, et al.
Atherosclerosis|December 21, 2007
Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion moleculesC Tikellis, K A Jandeleit-Dahm, K Sheehy, et al.
Diabetologia|October 23, 2009
Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosisY Pham, Y Tu, T Wu, et al.
Diabetologia|December 3, 2013
Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) miceE Di Marco, S P Gray, P Chew, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Drug Targets. Cardiovascular & Haematological Disorders|March 1, 2006
Preventing atherosclerosis with angiotensin-converting enzyme inhibitors: emphasis on diabetic atherosclerosisT J Allen, K A Jandeleit-Dahm
PPAR Research|March 27, 2012
The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetesM C Thomas, K A Jandeleit-Dahm, C Tikellis
Diabetologia|February 8, 2006
Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammationA C Calkin, M E Cooper, K A Jandeleit-Dahm, et al.
Diabetes & Metabolism|September 2, 2015
Linking RAGE and Nox in diabetic micro- and macrovascular complicationsC Koulis, A M D Watson, S P Gray, et al.
Current Pharmaceutical Design|September 28, 2007
PPARs and diabetes-associated atherosclerosisA C Calkin, K A Jandeleit-Dahm, E Sebekova, et al.
Diabetologia|July 3, 2008
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammationA C Calkin, S Giunti, K J Sheehy, et al.
Diabetologia|March 1, 2012
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetesK Huynh, H Kiriazis, X-J Du, et al.
Atherosclerosis|December 21, 2007
Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion moleculesC Tikellis, K A Jandeleit-Dahm, K Sheehy, et al.
Diabetologia|October 23, 2009
Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosisY Pham, Y Tu, T Wu, et al.
Diabetologia|December 3, 2013
Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) miceE Di Marco, S P Gray, P Chew, et al.
Pageof 1